Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood disorder survey in bangladesh reveals hidden genetic burden

NCT ID NCT07207551

Knowledge-focused Sponsor: Bangladesh Bioscience Research Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how often hemoglobin disorders (like thalassemia and sickle cell disease) occur in people visiting a hospital in Chattogram, Bangladesh. Researchers tested blood samples from 760 volunteers using advanced methods to find different hemoglobin types. The goal was to gather information that could help improve genetic counseling and public health planning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

760 people

The number who actually took part.

Started

Jun 2023

Finished

Sep 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Population will consist of individuals from the selected community and healthcare facilities who meet the inclusion criteria. Participants of all ages and both sexes will be included, provided they give informed consent and have not received a blood transfusion within the last three months. The population is expected to represent a cross-section of healthy individuals and those with suspected or confirmed hemoglobinopathies, allowing for assessment of hemoglobin variants and related biochemical parameters.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Residents of the Chattogram metropolitan area. * All ages and both sexes with informed consent. * Willing to provide venous blood samples. * No blood transfusion in the past 3 months. Exclusion Criteria: * Refusal or withdrawal of consent. * Blood transfusion within the last 3 months. * Pregnant women. * Inadequate or hemolyzed blood samples.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemoglobinopathies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

beta thalassemia hemoglobinopathy inherited hemoglobinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemoglobinopathies

Contacts and locations

Locations

  • University of Science and Technology Chittagong (USTC)

    Khulshi, Chattogram, 4203, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.